Benjamin Wu

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

Min Zhu, Benjamin Wu, Christian Brandl et al. · Clinical Pharmacokinetics · 2016 · 203 citations

Bispecific T-cell Engager, Tumor Immunology, Cancer Immunosurveillance +8

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Kari M. Morrissey, Mathilde Marchand, Hina Patel et al. · Cancer Chemotherapy and Pharmacology · 2019 · 86 citations · Full text

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Marc Peeters, A. H. Strickland, Mikhail Lichinitser et al. · British Journal of Cancer · 2013 · 79 citations · Full text

Placebo-controlled Phase 2, Oncology, Medicine +8

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

Janet Clarke, Will Leach, Susanne Pippig et al. · Regulatory Toxicology and Pharmacology · 2004 · 76 citations

Immunohematology, Immunocytochemical Technique, Allergy +11

Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity

Yang Xu, Yasmine M. Hijazi, A. Wolf et al. · CPT Pharmacometrics & Systems Pharmacology · 2015 · 66 citations · Full text

Immunology, Immunologic Mechanism, Pharmacotherapy +19